Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

RBOT vs DBVT vs ISRG vs ALKS vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RBOT
Vicarious Surgical Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$4M
5Y Perf.-99.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.+14.0%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+90.3%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.83B
5Y Perf.+111.2%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+37.0%

RBOT vs DBVT vs ISRG vs ALKS vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RBOT logoRBOT
DBVT logoDBVT
ISRG logoISRG
ALKS logoALKS
SYK logoSYK
IndustryMedical - DevicesBiotechnologyMedical - Instruments & SuppliesBiotechnologyMedical - Devices
Market Cap$4M$1690.08T$159.85B$5.83B$109.33B
Revenue (TTM)$0.00$0.00$10.58B$1.56B$25.12B
Net Income (TTM)$-42M$-168M$2.98B$153M$3.25B
Gross Margin66.3%65.4%63.5%
Operating Margin30.5%12.3%22.4%
Forward P/E43.3x24.5x19.1x
Total Debt$8M$22M$303M$70M$14.86B
Cash & Equiv.$3M$194M$3.37B$1.12B$4.01B

RBOT vs DBVT vs ISRG vs ALKS vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RBOT
DBVT
ISRG
ALKS
SYK
StockSep 20May 26Return
Vicarious Surgical … (RBOT)1000.2-99.8%
DBV Technologies S.… (DBVT)100114.0+14.0%
Intuitive Surgical,… (ISRG)100190.3+90.3%
Alkermes plc (ALKS)100211.2+111.2%
Stryker Corporation (SYK)100137.0+37.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: RBOT vs DBVT vs ISRG vs ALKS vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. RBOT and DBVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
RBOT
Vicarious Surgical Inc.
The Growth Leader

RBOT ranks third and is worth considering specifically for growth.

  • 31.5% revenue growth vs DBVT's -100.0%
Best for: growth
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +100.5% vs RBOT's -93.8%
Best for: momentum
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs SYK's 179.2%
  • Lower volatility, beta 1.00, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.00, current ratio 4.87x
Best for: growth exposure and long-term compounding
ALKS
Alkermes plc
The Quality Angle

Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.

Best for: healthcare exposure
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 34 yrs, beta 0.52, yield 1.2%
  • PEG 1.28 vs ISRG's 1.99
  • Lower P/E (19.1x vs 43.3x), PEG 1.28 vs 1.99
  • Beta 0.52 vs RBOT's 1.85, lower leverage
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthRBOT logoRBOT31.5% revenue growth vs DBVT's -100.0%
ValueSYK logoSYKLower P/E (19.1x vs 43.3x), PEG 1.28 vs 1.99
Quality / MarginsISRG logoISRG28.2% margin vs DBVT's 0.3%
Stability / SafetySYK logoSYKBeta 0.52 vs RBOT's 1.85, lower leverage
DividendsSYK logoSYK1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+100.5% vs RBOT's -93.8%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs RBOT's -164.5%, ROIC 15.0% vs -116.2%

RBOT vs DBVT vs ISRG vs ALKS vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RBOTVicarious Surgical Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

RBOT vs DBVT vs ISRG vs ALKS vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

SYK and DBVT operate at a comparable scale, with $25.1B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ALKS's 9.8%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
RevenueTrailing 12 months$0$0$10.6B$1.6B$25.1B
EBITDAEarnings before interest/tax-$42M-$112M$3.8B$212M$6.3B
Net IncomeAfter-tax profit-$42M-$168M$3.0B$153M$3.2B
Free Cash FlowCash after capex-$40M-$151M$2.8B$392M$4.3B
Gross MarginGross profit ÷ Revenue+66.3%+65.4%+63.5%
Operating MarginEBIT ÷ Revenue+30.5%+12.3%+22.4%
Net MarginNet income ÷ Revenue+28.2%+9.8%+12.9%
FCF MarginFCF ÷ Revenue+26.8%+25.1%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+23.0%+28.2%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+58.1%+91.5%+18.8%-4.1%+56.0%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ALKS leads this category, winning 3 of 7 comparable metrics.

At 24.5x trailing earnings, ALKS trades at a 57% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs ISRG's 2.63x — a lower PEG means you pay less per unit of expected earnings growth.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
Market CapShares × price$4M$1690.08T$159.8B$5.8B$109.3B
Enterprise ValueMkt cap + debt − cash$9M$1690.08T$156.8B$4.8B$120.2B
Trailing P/EPrice ÷ TTM EPS-0.07x-0.75x57.19x24.47x33.98x
Forward P/EPrice ÷ next-FY EPS est.43.35x19.06x
PEG RatioP/E ÷ EPS growth rate2.63x2.29x
EV / EBITDAEnterprise value multiple43.28x17.01x19.76x
Price / SalesMarket cap ÷ Revenue15.88x3.95x4.35x
Price / BookPrice ÷ Book value/share0.33x0.65x9.10x3.25x4.87x
Price / FCFMarket cap ÷ FCF64.18x12.14x25.53x
ALKS leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 5 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-3 for RBOT. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs RBOT's 1/9, reflecting strong financial health.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-3.3%-130.2%+16.9%+8.8%+15.0%
ROA (TTM)Return on assets-164.5%-89.0%+14.8%+5.4%+6.9%
ROICReturn on invested capital-116.2%+15.0%+18.9%+11.4%
ROCEReturn on capital employed-134.6%-145.7%+16.5%+14.2%+13.0%
Piotroski ScoreFundamental quality 0–914676
Debt / EquityFinancial leverage0.79x0.13x0.02x0.04x0.66x
Net DebtTotal debt minus cash$5M-$172M-$3.1B-$1.0B$10.8B
Cash & Equiv.Liquid assets$3M$194M$3.4B$1.1B$4.0B
Total DebtShort + long-term debt$8M$22M$303M$70M$14.9B
Interest CoverageEBIT ÷ Interest expense-189.82x32.30x6.72x
ISRG leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ISRG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $18 for RBOT. Over the past 12 months, DBVT leads with a +100.5% total return vs RBOT's -93.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs RBOT's -79.4% — a key indicator of consistent wealth creation.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
YTD ReturnYear-to-date-78.2%+3.6%-19.9%+23.8%-17.8%
1-Year ReturnPast 12 months-93.8%+100.5%-16.4%+15.2%-24.5%
3-Year ReturnCumulative with dividends-99.1%+18.1%+48.5%+13.2%+2.4%
5-Year ReturnCumulative with dividends-99.8%-68.3%+61.7%+61.7%+17.5%
10-Year ReturnCumulative with dividends-99.8%-87.1%+549.2%-12.0%+179.2%
CAGR (3Y)Annualised 3-year return-79.4%+5.7%+14.1%+4.2%+0.8%
ISRG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than RBOT's 1.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs RBOT's 4.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.85x1.26x1.00x1.00x0.52x
52-Week HighHighest price in past year$13.75$26.18$603.88$36.60$404.87
52-Week LowLowest price in past year$0.35$7.53$427.84$25.17$284.97
% of 52W HighCurrent price vs 52-week peak+4.0%+75.3%+74.5%+95.6%+70.5%
RSI (14)Momentum oscillator 0–10037.147.443.660.526.6
Avg Volume (50D)Average daily shares traded24K252K1.8M2.2M2.1M
Evenly matched — ALKS and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

SYK leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DBVT as "Buy", ISRG as "Buy", ALKS as "Buy", SYK as "Buy". Consensus price targets imply 134.8% upside for DBVT (target: $46) vs 31.5% for ALKS (target: $46). SYK is the only dividend payer here at 1.18% yield — a key consideration for income-focused portfolios.

MetricRBOT logoRBOTVicarious Surgica…DBVT logoDBVTDBV Technologies …ISRG logoISRGIntuitive Surgica…ALKS logoALKSAlkermes plcSYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$46.33$622.60$46.00$389.62
# AnalystsCovering analysts15552850
Dividend YieldAnnual dividend ÷ price+1.2%
Dividend StreakConsecutive years of raises0034
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%+0.5%0.0%
SYK leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALKS leads in 1 (Valuation Metrics). 1 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

RBOT vs DBVT vs ISRG vs ALKS vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RBOT or DBVT or ISRG or ALKS or SYK a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RBOT or DBVT or ISRG or ALKS or SYK?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

5x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — RBOT or DBVT or ISRG or ALKS or SYK?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RBOT or DBVT or ISRG or ALKS or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Vicarious Surgical Inc. 's 1. 85β — meaning RBOT is approximately 254% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RBOT or DBVT or ISRG or ALKS or SYK?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RBOT or DBVT or ISRG or ALKS or SYK?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RBOT or DBVT or ISRG or ALKS or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 24. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 134. 8% to $46. 33.

08

Which pays a better dividend — RBOT or DBVT or ISRG or ALKS or SYK?

In this comparison, SYK (1.

2% yield) pays a dividend. RBOT, DBVT, ISRG, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is RBOT or DBVT or ISRG or ALKS or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RBOT and DBVT and ISRG and ALKS and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RBOT is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ISRG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while RBOT, DBVT, ISRG, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.